Severe hypothyroidism can affect a variety of organs and can develop atypical manifestations. Peripheral precocious puberty may be secondary to other endocrinological diseases, which must be taken into account in the differential diagnosis in order to avoid unnecessary additional tests. Van Wyk–Grumbach syndrome is an infrequent manifestation characterized by severe hypothyroidism and incomplete precocious puberty. Diagnosis is made by clinical and complementary tests, and the main treatment goal is to achieve euthyroidism through hormone replacement. Prognosis is good once the treatment is established. The aim of this study is to review the available literature about Van Wyk–Grumbach syndrome following the PRISMA statement, and to present the first clinical case published in Spain. We have included the articles published during the period from 1905 to week 40 of 2022. A total of 68 articles have been selected for study and analysis, within which there are 99 published clinical cases. Girls accounted for 92.1% of cases (median age at the diagnosis 8.5 years). Metrorrhagia was the most prevalent symptom, present in 80.5% of the girls. Abdominal ultrasound was performed in 93.3% of the girls and 97.8% of them had at least one ovarian cyst. All cases were treated with levothyroxine, responding satisfactorily after the first doses of treatment. To conclude, Van Wyk–Grumbach syndrome is characterized by severe hypothyroidism and incomplete precocious puberty, which is important to keep in mind in order to avoid complementary exams and unnecessary surgical interventions.
This systematic review was conducted with the objective of understanding the efficacy and safety of proton pump inhibitors (PPIs) in the pediatric population. We used PubMed to identify randomized controlled trials (RCTs) published between 1 June 2010 and 30 June 2023, performed in patients from birth to 18 years old with gastroesophageal reflux disease (GERD) who received treatment with any PPI. This literature search yielded 76 articles and 13 of these met the inclusion criteria. For infants, PPIs were equal to placebos in reducing GERD symptoms in four articles. In one article, the numbers of GER episodes and esophageal acid exposures were lower in infants who received PPIs in the left lateral position, but there was generally no significant improvement in symptoms. In another publication, the combination of PPIs and feeding modifications (FMs) was not more effective than PPIs alone. For children and adolescents, PPIs were effective in improving symptoms and achieving endoscopic healing, which was subsequently maintained. To conclude, PPIs are not effective in reducing the symptoms related to GERD in infants but are effective in older children, where histological remission can be seen. Generally, PPIs are well tolerated, but it is important to remember the possible adverse events (AEs), especially if PPIs are used for an extended period.
Background/Objectives: Disease-related malnutrition (DRM) is the most common type of malnutrition in industrialized countries, and it has a high associated morbidity. Despite the existence of various screening tools for its detection, there is currently no consensus in the literature on which one is the most appropriate for clinical use. The aim of this systematic review is to update the available evidence on pediatric nutritional screening tools and to compare their validity and applicability. Methods: A systematic review of the literature was conducted using the MEDLINE (PubMed) database, selecting articles related to nutritional screening tools in the pediatric population. A quality assessment was carried out using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). Results: A total of 200 articles were identified, of which 11 were included in the review. They include a total of 9,573 patients (mean age of 6.7 years and 49% female) from different countries. Eight screening tools were found, and three of them were the most employed: the Screening Tool for Risk on Nutritional Status and Growth (STRONGkids), the Screening Tool for the Assessment of Malnutrition in Pediatric (STAMP), and the Pediatric Yorkhill Malnutrition Score (PYMS). A high level of heterogeneity was observed among the selected studies without a gold standard for comparison. Conclusions: Despite the heterogeneity, the PYMS seems to have the greatest capacity to detect pediatric patients at nutritional risk and should therefore be considered when choosing a nutritional screening tool.
Non-invasive ventilation (NIV) is now considered the first-line treatment for respiratory distress syndrome in preterm infants. We aimed to evaluate the rates of non-invasive ventilation failure rate in very preterm infants, as well as to identify its predictors and associated outcomes. We designed a single-center retrospective cohort study including infants ≤32 weeks gestational age and ≤1500 g. The NIV failure was defined as the need for intubation at II (OR 6.22; 95% CI 1.36–28.3). These infants were significantly smaller in GA and weight. Higher FiO2 during resuscitation (OR 1.14; 95% CI 1.06–1.22) and after surfactant administration (OR 1.17; 95% CI 1.05–1.31) represented independent risk factors for NIV failure. In conclusion, NIV failure is frequent and it could be predicted by a higher oxygen requirement during resuscitation and a modest response to surfactant therapy. Importantly, this NIV failure is associated with worse clinical outcomes.
This is a prospective, multicenter study of a cohort of 224 cystic fibrosis (CF) patients treated with CF transmembrane conductance regulator (CFTR) modulators (CFTRm). Our aim was to prospectively analyze the effect of CFTRm treatment on fat‐soluble vitamin serum levels. Demographic and clinical data were recorded, and fat‐soluble vitamin levels were analyzed at baseline, and at 6 and 12 months after starting treatment. Two groups were analyzed separately: patients receiving dual therapy lumacaftor/ivacaftor or tezacaftor/ivacaftor (Lum/Tez+Iva), and those on triple therapy with elexacaftor/tezacaftor/ivacaftor (ETI). We found that treatment with ETI produced a significant increase in vitamin D and A levels within the first 6 months, which was maintained at 12 months. However, with dual therapy, we observed an increase only in vitamin A levels within the first 6 months, which was not maintained at 12 months. No differences were found in vitamin E serum levels between the groups.
Background: Bronchopulmonary dysplasia (BPD) is a major complication among preterm infants, and nutrition plays a crucial role in its prevention and management. While the nutritional superiority of human milk over preterm formula is well documented, comparisons of the protective benefits of mother’s own milk (MOM) versus donor human milk (DHM) in preterm infants are lacking. We aim to investigate if and how the use of MOM or DHM at the initiation of enteral feeding influences the development of BPD and other respiratory outcomes. Methods: This study evaluated the incidence of BPD and other prematurity outcomes in a cohort of 159 very preterm infants (≤32 weeks GA) who commenced enteral feeding with either MOM or DHM. Results: Enteral feeding was initiated with MOM in 75.5% of the infants and DHM in 24.5%. The incidence of BPD was 24.8% (39 infants), and 10.4% (16 infants) developed moderate-to-severe BPD. Univariate and multivariate analyses revealed no significant differences between the MOM and DHM groups in the rates of BPD, other respiratory outcomes, or key prematurity-related morbidities. Conclusions: Despite the unique bioactive properties of MOM, these findings suggest that DHM is a valid alternative that does not significantly increase the incidence of BPD or other clinical outcomes. Further studies are required to determine the relative contributions of milk volumes and feeding practices to the observed findings.